Equillium registers Phase 1 trial of EQ504 for ulcerative colitis
A new first-in-human study of oral EQ504 was listed on ClinicalTrials.gov, with dosing expected to begin in October 2026.
Equillium had one registry update this week, a newly posted early-stage trial for its ulcerative colitis candidate.
- EQ504, an oral drug being tested for ulcerative colitis, has a Phase 1 trial registered as "not yet recruiting" under NCT07869225. The study is a first in human, three-part randomized, double-blind, placebo-controlled dose escalation trial to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of EQ504 following single ascending dose and multiple ascending dose administration, with an optional food effect cohort in healthy volunteers.1 The trial plans to enroll approximately 40 subjects in the single ascending dose part, 30 in the multiple ascending dose part, and 8 in the food effect part.1 It is expected to start in October 2026 and will run at one site, Veritus Research in Melbourne, Australia.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.